Mainz Biomed Announces First Quarter 2022 Results
BERKELEY, US – MAINZ, Germany – April 12, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022. Key Highlights Continued to ramp up EU commercial activities for ColoAlert, the […]
Mainz Biomed Completes Successful Pre-Submission Process with the U.S. FDA for ColoAlert’s Pivotal Clinical Trial
Multi-Center Study on Track to Commence in Late 2022 Initiated Reimbursement Process with The Centers for Medicare and Medicaid Services BERKELEY, US – MAINZ, Germany – March 31, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it […]
Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer, will ring the closing bell at Nasdaq MarketSite in New York’s Times Square today, Monday, March 21st, 2022 […]
Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
Cutting Edge IVD Developer Sentinel Chosen to Provide Automated FIT Analysis System Leading Clinical Research Organization Alcedis Selected to Manage the Study ColoFuture on track to complete enrollment in 2H 2022 BERKELEY, Calif. and MAINZ, Germany, March 17, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing […]
Mainz Biomed Announces Year End 2021 Results
BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today key strategic and operational results for the year ended December 31, 2021. Key Highlights and 2021 Accomplishments Executed successful U.S. Initial Public Offering […]
Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
Mainz Biomed joins a collective of physicians, healthcare professionals, laboratories and healthcare organizations as part of the international Colorectal Cancer Awareness Month initiative BERKELEY, US – MAINZ, Germany – March 2nd, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced […]
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug Administration BERKELEY, US – MAINZ, Germany – February 23rd, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its pre-submission filed with the U.S. Food […]
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in Europe. Laboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists, chemists, doctors and other specialists. BERKELEY, US […]
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, US – MAINZ, Germany – February 9th, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment […]
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier at-home screening test for colorectal cancer BERKELEY, Calif. and MAINZ, Germany, Feb. 04, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early […]
